Risk Management

Overview

Risk management in pharmacovigilance focuses on understanding important identified risks, important potential risks, and areas of missing information, and on defining appropriate actions to monitor or minimize those risks.

Mediature GxP Solutions Pvt. Ltd. (MGS) supports Marketing Authorization Holders, pharmaceutical companies, CROs, and other life-sciences organizations with preparation, review, maintenance, and implementation support for pharmacovigilance risk-management activities.

Our approach integrates safety data, signal information, aggregate reports, product labeling, exposure information, regulatory commitments, risk-minimization measures, and benefit-risk considerations to support a structured and traceable risk-management process.

Our Risk Management Services

Risk Management Plan Support

Preparation, review, and maintenance support for Risk Management Plans based on the product safety profile and applicable regulatory requirements.

Safety Specification Support

Support for defining and documenting:

• Important identified risks
• Important potential risks
• Missing information
• Relevant safety concerns
• Supporting evidence

Pharmacovigilance Plan Support

Development of activities intended to further characterize, monitor, or evaluate identified safety concerns.

Risk-Minimization Support

Support for defining, documenting, and tracking routine or additional risk-minimization measures where applicable.

Benefit-Risk Evaluation Support

Assessment support for integrating emerging safety information with available evidence on product benefit.

Risk Review & Update

Periodic review of the risk-management framework based on:

• New ICSRs
• Literature findings
• Signal assessments
• Aggregate reports
• Regulatory actions
• Label changes
• New clinical or post-marketing information

Risk-Minimization Effectiveness Support

Support for evaluating whether risk-minimization measures are being implemented and achieving their intended objectives where such evaluation is required.

Regulatory Commitment Tracking

Support for tracking risk-management commitments, due dates, actions, updates, and associated documentation.

Key Risk Management Areas

Depending on the product and lifecycle stage, MGS may support assessment of:

• Important identified risks
• Important potential risks
• Missing information
• Special populations
• Pregnancy and breastfeeding
• Drug interactions
• Medication errors
• Off-label use
• Overdose
• Misuse and abuse
• Long-term safety concerns
• Serious adverse reactions
• Rare adverse reactions
• Product-specific safety concerns
• Emerging signals
• Risk communication
• Risk-minimization measures
• Regulatory commitments

Risk-Minimization Measures

Depending on the product and applicable requirements, risk-minimization activities may include:

Routine Measures

• Product labeling
• Prescribing information
• Patient information
• Warnings and precautions
• Contraindications
• Monitoring recommendations

Additional Measures

Where required, additional measures may include:

• Educational materials
• Healthcare professional communication
• Patient guides
• Controlled-access measures
• Additional monitoring tools
• Other product-specific interventions

Our Approach

• Identify

Review available safety information to define important risks and areas of uncertainty.

• Characterize

Assess clinical significance, frequency, severity, preventability, affected populations, and available evidence.

• Plan

Define pharmacovigilance activities and appropriate risk-minimization measures.

• Implement

Support execution and documentation of agreed risk-management activities.

• Monitor

Review new safety information, signals, aggregate data, literature, and regulatory developments.

• Evaluate & Update

Assess effectiveness, update risk characterization, and revise the risk-management framework when new evidence becomes available.

Typical Deliverables

Depending on scope, MGS can provide:

• Risk Management Plan support
• Safety specification
• Pharmacovigilance plan
• Risk classification support
• Risk-minimization documentation
• Benefit-risk evaluation support
• Risk-management tracker
• Regulatory commitment tracker
• Literature and signal input
• RMP update support
• Effectiveness-evaluation support
• Review and quality-control documentation

Why Choose MGS

Integrated Safety Perspective

MGS connects ICSR data, literature, signal management, aggregate reporting, and regulatory information within the risk-management process.

Lifecycle-Based Approach

Risk management is treated as an evolving activity that changes as new safety information becomes available.

Evidence-Based Evaluation

Our approach focuses on documented evidence, clinical relevance, and traceable safety decisions.

Flexible Support Model

MGS can support complete risk-management documentation or selected activities such as safety specification, risk review, tracking, or benefit-risk evaluation.

Quality & Regulatory Integration

Risk-management activities can be aligned with broader PV quality systems, reporting obligations, and regulatory commitments.

Who We Support

MGS can provide Risk Management support for:

• Marketing Authorization Holders
• Pharmaceutical companies
• Biopharmaceutical organizations
• CROs
• Generic-drug companies
• Product-license partners
• Organizations maintaining product-specific risk-management plans
• Companies requiring ongoing safety-risk review